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The porphyrias are a group of clinical
symptoms associated with inherited or
induced disturbances in heme biosynthesis.
Porphyria cutanea tarda (PCT), the most
common hepatic porphyria, occurs in
humans with an inherited deficiency of
hepatic uroporphyrinogen decarboxylase
(UROD), an enzyme involved in the decar-
boxylation of uroporphyrinogen to copro-
porphyrinogen. The excess of hepatic uro-
porphyrinogen resulting from this deficien-
cy is eventually excreted in the urine as uro-
porphyrin. However, alcohol ingestion is a
common precipitating cause (1-3).
Following a disastrous hexachloroben-
zene (HCB) poisoning in southeastern
Turkey in the 1960s, victims displayed
signs ofdisturbed heme synthesis, resulting
in massive urinary excretion of porphyrins
and hepatic accumulation of porphyrins,
consistent with PCT (4,5). PCT was also
reported in industrial workers producing
the herbicides 2,4-dichlorophenoxyacetic
acid and 2,4,5-trichlorophenoxyacetic acid
(6,7). 2,3,7,8-Tetrachlorodibenzo-p-dioxin
(TCDD) was found to be a contaminant in
these herbicides. TCDD is a potent por-
phyrinogenic agent in rats and mice
(8-10). The Seveso accident in Italy
involving human exposure to TCDD
revealed an increase in urinary copropor-
phyrin (11). Human exposure to a com-
plex mixture ofpolychlorinated dibenzofu-
rans (PCDFs) and biphenyls (PCBs) in the
Taiwanese Yu-Cheng poisoning resulted in
elevated urinary excretion ofuroporphyrin
and aminolevulinic acid (ALA), both pre-
cursors ofheme synthesis (12).
Porphyrin accumulation has also been
observed under field conditions and in
experimental animals. Herring gulls (Larus
argentatus) from colonies throughout the
Great Lakes showed elevated hepatic por-
phyrin concentrations in comparison to
colonies from coastal areas (13). The Great
Lakes have been associated with a high
contamination ofpolyhalogenated aromat-
ic hydrocarbons such as polychlorinated
dibenzo-p-dioxins (PCDDs), PCDFs, and
PCBs.
In laboratory animals, a clear induction
of PCT-like signs, i.e., accumulation of
hepatic uroporphyrinogen and heptacar-
boxylic porphyrin, induction of6-aminole-
vulinic acid synthetase (ALAS) activity, and
inhibition of UROD activity, have been
observed after exposure to TCDD and relat-
ed compounds. Jones and Sweeney (14)
studied the porphyrinogenic action of
TCDD in genetically responsive C57BL/6
and nonresponsive DBA mice. Susceptibility
to porphyria correlated with aryl hydrocar-
bon hydroxylase (AHH) inducibility, indi-
cating that the aryl hydrocarbon (Ah) recep-
tor may be involved in this response. In
addition, chronic exposure ofrats to TCDD
caused hepatic porphyria, which could not
be established after acute exposure to TCDD
(9). Accumulation of hepatic porphyrins in
mice during a 10-week feeding study was
also found after exposure to 3,3',4,4',5,5'-
hexachlorobiphenyl (PCB 169) or Kane-
chlor-500 administration (15). After 3 weeks
of dietary exposure, porphyrins were mani-
fest, ALAS activity was increased, and
UROD activitywas decreased.
In spite of a broad range of adverse
human health effects observed after high-
level exposure (16,17), the major public
concern involves the protection ofthe gen-
eral population against these compounds
due to background exposure. The world-
wide occurrence of PCDDs, PCDFs, and
PCBs has led to concern and a need for risk
assessment with regard to the general popu-
lation. This need is strengthened by the
adverse effects on various (neuro)develop-
mental parameters at low-level, background
exposure (18-21).
The mechanism of action of TCDD
and related compounds involves an initial
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binding to the Ah receptor (22,23). A clear
correlation between the Ah receptor-medi-
ated biochemical and toxic effects was
observed in a number oflaboratory studies
(16,17). As a result, quantitative struc-
ture-activity relationships were obtained,
subsequently leading to the development of
the toxic equivalency concept for this
group ofcompounds. In this concept, each
compound is assigned a toxic equivalency
factor (TEF) that reflects its relative toxic
and biochemical potency to TCDD, the
most potent compound, assigned a TEF
value of 1. A prerequisite for the TEF con-
cept is additive toxicity, which is supported
by in vivo studies with mixtures ofPCDDs
and PCDFs (24), mixtures ofPCDFs (25),
mixtures of TCDD and PCBs (26,27),
and by in vitro studies with mixtures of
PCBs and PCDFs (28). The Ah receptor-
mediated toxic potency of mixtures of
PCDDs, PCDFs, and PCBs is therefore
calculated by the summation of the toxic
equivalents (TEQs), i.e., the product ofthe
concentration and the TEF value of each
individual congener.
However, antagonistic as well as syner-
gistic effects have been found after
co-administration of binary mixtures in
single-dose, short-term experiments in
rodents using hepatic cytochrome P450
isozymes, immunotoxicity, and terato-
genicity as endpoints (29-33). After chron-
ic exposure to 2,2',4,4',5,5'- and 3,3',4,
4',5,5'-hexabromobiphenyl in rats, Jensen
and Sleight (34) found synergism in hepat-
ic tumor promotion.
By using interim TEF values
(17,35,36), some co-planar and mono-
ortho-substituted PCBs account for a sig-
nificant contribution to the total TEQ in
biotic samples (37-39). On this basis, and
as a consequence ofthe nonadditive effects
reported, toxicity studies involving mixture
exposure using PCBs are important for risk
assessment. For the PCB congeners, rele-
vant PCBs were chosen from each PCB
group (di-ortho-substituted, mono-ortho-
substituted, and co-planar PCBs). This
choice was based on high relative toxicity
and concentration in human milk and fat
tissue (40-42).
Additionally, a subchronic dosing
regime was chosen in view ofextrapolation
for risk assessment of these compounds.
Since risk assessment based on intake dose
does not involve kinetic aspects ofthe com-
pound to be evaluated, extrapolation based
on intake dose will fail when large kinetic
differences exist between species (43,44).
In the present study, subchronic effects
on hepatic porphyrin accumulation were
studied in rats fed diets containing 2,2',
4',5,5'-hexachlorobiphenyl (PCB 153),
2,3,3',4,4',5-hexachlorobiphenyl (PCB
156), 3,3',4,4',5-pentachlorobiphenyl
(PCB 126), or TCDD. At the same time,
the single PCB congeners were co-adminis-
tered with TCDD to study possible inter-
active effects. The concentration ratios
used were comparable with those found in
human milkand fat samples.
Materials and Methods
Chemicals. TCDD (purity 99%) was syn-
thesized by Dow Chemical (Midland,
Michigan). PCB 126 (purity 99%) as used
in the subchronic study was obtained from
Schmidt B.V. (Amsterdam). PCB 153
(purity >99.9%) as used in the subchronic
study was synthesized according to
Hutzinger and Safe (45) as described earli-
er (46). PCB 126 and PCB 153 (purities
>98%) as used in the in vitro inhibition
experiment were from Ultra Scientific.
PCB 156 was synthesized according to
Mullin and co-workers (47) as previously
described (26). Uroporphyrinogen I,
coproporphyrin III, (copro III), and a
marker kit containing 2-, 4-, 5-, 6-, 7-, and
8-carboxyl porphyrin isomers I were
obtained from Porphyrin Products Inc.
(Logan, Utah). Acetanilide, 4-hydroxyac-
etanilide, 3-hydroxyacetanilide, and bovine
serum albumin (BSA) were purchased from
Sigma Chemical Co. (St. Louis, Missouri).
Methoxyresorufin was purchased from
Molecular Probes Inc. (Eugene, Oregon).
The other chemicals used were ofanalytical
grade and were obtained from Merck AG
(Darmstadt, Germany), BDH Chemicals
Ltd. (Poole, Dorset, UK), or Sigma.
Animals and treatment. Female
Sprague-Dawley rats [Iva: S/V 50 (SD)],
Ivanovas (Kissley, Germany), 7 weeks old,
weighing about 150 g, were kept on a stan-
dard laboratory diet (Nafag 890, Gossau,
Switzerland) for 1 week before the experi-
ment. One day before the start of the 13-
week feeding experiments, the rats were
randomly divided into groups ofeight (first
experiment) or nine (second experiment)
animals with a similar mean and standard
deviation in body weights. The diets, in
pulverized form, were prepared according
to Pluess and co-workers (24) and con-
tained PCB 153, PCB 156, PCB 126,
TCDD, or combinations ofthe PCBs with
TCDD (Tables 1 and 2). Water and food
were given adlibitum. The rats were housed
three or four per cage and held under con-
trolled conditions of temperature (200C)
and lighting (12-hrlight/darkcycle).
After termination of the experiments,
the animals were killed under diethylether
anesthesia by taking blood of the inferior
vena cava. The liver was removed, rinsed in
physiological saline solution, and weighed.
Parts ofthe liverwere frozen in liquid nitro-
gen and stored at -700C until cytochrome
Table 1. Dose groups, daily doses of PCB 156, PCB 126, and/orTCDD, and hepatic porphyrin levels after 13
weeks on diets containing PCB 126, PCB 156, and/orTCDD (means ± SE, n=8)
TCDD
(pg/kg)
0
0.2
0.4
0.7
5
20
0
0
0
0.4
0.4
0.4
5
5
5
0
0
0
5
5
5
Amount in diet
PCB 126
(pg/kg)
0
0
0
0
0
0
7
50
180
7
50
180
7
50
180
0
0
0
0
0
0
PCB 156
(mg/kg)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1.2
6
12
1.2
6
12
TCDD
(ng/kg/day)
0
14
26
47
320
1024
0
0
0
27
26
23
315
306
269
0
0
0
317
305
290
Daily dosea
PCB 126
(pg/kg/day)
0
0
0
0
0
0
0.47
3.18
10.1
0.48
3.25
10.4
0.44
3.06
9.68
0
0
0
0
0
0
PCB 156
(pg/kg/day)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
81
365
729
76
366
696
Porphyrins
(pg/g liver)
0.494 ± 0.059b
0.494 ± 0.039
0.686 ± 0.066
0.827 ± 0.073*
0.954 ± 0.053*
0.889 ± 0.059*
0.764 ± 0.117
0.853 ± 0.086*
0.841 ± 0.075*
0.694 ± 0.061
1.05 ± 0.10**
1.01 ±0.06c**
0.899 ± 0.062
1.12 ± 0.10
0.913 ± 0.037
0.607 ± 0.061
0.956 ± 0.098b*
1.17 ± 0.11*
1.14 0.09t
1.19 0.08
1.18 0.15b
aDaily doses are estimated average values based on estimated food consumption, dietary level of com-
pound, and average bodyweight overthe 13-weekfeeding period.
bn=7.
cn= 6.
*Significantfrom control(leastsignificant difference test, p<0.05).
**Significant from 0.4pg TCDD/kg alone (leastsignificant difference test, p<0.05).
tSignificantfrom 1.2 mg PCB 156/kg alone (leastsignificant difference test, p <0.05).
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Table 2. Dose groups, daily doses of PCB 153 and/or TCDD, and hepatic porphyrin levels after 13 weeks
on diets containing PCB 153 and/orTCDD (means ± SE, n=9)
Amount in diet Daily dose"
TCDD (pg/kg) PCB 153 (mg/kg) TCDD (ng/kg/day) PCB 153 (mg/kg/day) Porphyrins(pg/g liver)
o a 0 0 1.9±0.5
0 10 0 0.72 2.8± 1.6
0 30 0 2.07 1.4± 0.3b
0 100 0 6.61 3.0 ± 0.9
0.5 0 33.4 0 1.9 ± 0.5
0.5 10 33.9 0.68 300 ± 203*
0.5 30 32.6 1.95 969 ± 270*
0.5 100 32.0 6.40 1223 ±326*
5 0 320 0 2.5 ± 0.3
5 10 318 0.64 22.0 ± 6.4*
5 30 301 1.81 1527 ±480*
5 100 293 5.85 1094 ±393*
"Estimated average value based on estimated food consumption, dietary level of compound, and average
bodyweight overthe 13-weekfeeding period.
bn =8.
*Significantfrom PCB 153 orTCDD at corresponding dose alone (least significant difference test, p<0.05).
P450 activity measurements, or at -20°C
until porphyrin analyses. The same part of
the liver was used for the same type of
analysis for all animals.
Determination ofporphyrins. Total
hepatic porphyrin content was determined
according to the method ofSchwartz et al.
(48), as modified by Debets et al. (49),
using an acid-ethanol solution ofchloranil
(2,3,5,6-tetrachloro-1,4-benzoquinone)
and 100-pl samples of whole total-liver
homogenate, prepared as described earlier
(26). Fluorescence was measured in 96-
well multiplates at Xex 409 nm and kem
645 nm using a cytofluor multiwell plate
reader (Millipore B.V., Etten-Leur, the
Netherlands) and coproporphyrin III as a
standard.
The pattern ofporphyrins accumulated
in the livers were analyzed as described ear-
lier (50), after a porphyrin extraction-step
of liver homogenates (51) using reverse-
phase HPLC (LKB-Produkter, Bromma,
Sweden).
Cytochrome P450 measurements. Liver
microsomes were prepared according to the
method of Burke and Mayer (52).
Microsomal CYP1A2 activities in the first
experiment (PCB 126/PCB 156/TCDD)
were measured by the 4-hydroxylation of
acetanilide (4-OH-AA) according to Liu et
al. (53) as described earlier (26).
Microsomal CYP1A2 activities in the sec-
ond experiment (PCB 153/TCDD) were
measured by the demethylation of
methoxyresorufin (MROD), using the
same protocol as previously described for
ethoxyrosorufin-O-deethylase (54). The
substrate concentration used was 1.5 nM
methoxyresorufin. Western blot analysis of
CYP1A2 protein was determined in select-
ed samples of the second experiment as
described previously (55), with the excep-
tion that data are expressed as optical den-
sities/pg protein. Protein levels were spec-
trophotometrically measured according to
Bradford (56) by using a Bio-Rad Model
3550 microplate reader and BSA as a stan-
dard.
In vitro inhibition ofCYP1A2 activity.
Liver microsomes of rats treated with 100
mg PCB 153/kg diet in co-administration
with 5 pg TCDD/kg diet were used for the
in vitro inhibition of CYP1A2 measure-
ment using MROD as a marker. To test
the effect ofsubstrate on possible competi-
tion with an unknown binding inhibitor in
vitro, the concentration of methoxyre-
sorufin ranged from 1.5 nM to 30 nM
using microsomes of a responder and a
nonresponder. To test the effect of PCB
126 and PCB 153 on in vitro inhibition of
CYP1A2 activity, the methoxyresorufin
concentration used was 1.5 nM. PCB 153
or PCB 126 was dissolved in dimethyl sul-
foxide (DMSO) to a final concentration
ranging from 1.3 ng/ml to 13 pg/mi.
Samples were preincubated with 6 pl
DMSO or 6 pl of the tested PCB in
DMSO for 4 min. Reaction was started
with NADPH and followed for 2-3 min.
All measurements were performed in dupli-
cate. Data are expressed as a percentage of
CYP1A2 activity using 6 pl ofDMSO.
Statistics. Datawere analyzed for differ-
ences from controls with one-way analysis
of variance and the least significant differ-
ence test (p <0.05 for groups exposed to
one compound). Groups treated with mix-
tures oftwo compounds were compared to
the corresponding compounds alone. Two-
way analysis ofvariance was used to deter-
mine possible interactive effects (p <0.05).
Correlations between CYP1A2 activities
and hepatic porphyrin levels were exam-
ined by using Student's t-test (p <0.05).
Results
Total hepatic porphyrin levels are summa-
rized in Table 1 for groups fed diets con-
taining PCB 126 or PCB 156, with or
without co-administration ofTCDD (first
experiment). Table 2 shows the hepatic
porphyrin levels in rats fed on diets con-
taining PCB 153 and/or TCDD (second
experiment).
TCDD showed a dose-dependent
increase in hepatic porphyrin levels after 13
weeks ofdietary exposure in the first exper-
iment. This increase was also found for
PCB 126 or PCB 156, reaching maximum
levels about twice the control values (Table
1). However, it should be noted that the
control values of the first experiment were
lower than the control values ofthe second
experiment. The lowest dietary dose levels
for which a significant increase in hepatic
porphyrin accumulation was found were
0.7 pg TCDD/kg, 50 pg PCB 126/kg, and
6 mg PCB 156/kg. In addition, co-admin-
istration of 50 or 180 pg PCB 126/kg and
0.4 pg TCDD/kg resulted in a significant
increase in porphyrin accumulation as
compared to TCDD alone. Similarly, co-
administration of 1.2 mg PCB 156/kg and
5 pg TCDD/kg in the diet resulted in an
additional accumulation (1.9-fold) com-
pared to 1.2 mg PCB 156 alone.
In the second experiment, both PCB
153 and TCDD, when administered alone,
did not alter hepatic porphyrin levels com-
pared to controls up to levels of 100 mg
PCB 153/kg or 5 pg TCDD/kg, respec-
tively. Co-administration of any dose of
PCB 153 and TCDD resulted in a strong
accumulation ofhepatic porphyrins, which
was statistically different from control
groups and from the corresponding PCB
or TCDD group alone. The highest hepat-
ic porphyrin accumulation was 1500 pg/g
liver (i.e., about 800 times control levels).
At the highest dose groups (i.e., 100 mg
PCB 153/kg in co-administration with 5
pg TCDD/kg), four rats showed hardly
any porphyrin accumulation (84 ± 2 pg/g
liver), whereas in six rats a porphyrin level
was found which was nearly 1200 times
above control levels, i.e., 2215 ± 640 pg/g
liver. This extreme individual variation was
only observed in the experimental group
fed on diets containing 100 mg PCB
153/kg co-administered with 5 pg
TCDD/kg.
A qualitative HPLC analysis revealed
uroporphyrin III and heptacarboxylic por-
phyrin as the major accumulated por-
phyrins in porphyrinogenic livers (data not
shown).
Dose-dependent induction of4-hydrox-
ylation of acetanilide (4-OH-AA) by
TCDD, PCB 126, and PCB 156 has been
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reported before (26,27,57). Figure 1 shows
significant correlations between hepatic
CYP1A2 activities, measured as 4-OH-AA,
and hepatic porphyrin levels after TCDD
(Fig. IA), PCB 126 (Fig. IB), or PCB 156
(Fig. 1C) administration. The correlation
coefficients were 0.629 (p <0.001), 0.483 (p
<0.01), and 0.808 (p <0.001) for TCDD,
PCB 126, and PCB 156, respectively.
CYP1A2 activity, measured as MROD,
was increased 10-fold after TCDD (5
pg/kg diet) exposure in experiment 2
(Table 3). PCB 153 (100 mg/kg diet) gave
no increase in MROD activity compared
to controls. Co-administration of 0.5 or 5
pg TCDD/kg with 30 or 100 mg PCB
153/kg resulted in a decrease in MROD
activity compared to the corresponding
TCDD dose alone (Table 3). The por-
phyrinogenic rats exposed to 5 pg
TCDD/kg co-administered with 100 mg
PCB 153/kg had CYP1A2 activities of516
±57 nmol/mg/min (mean ± SE). The non-
3
-a,
a)
c.
a.
to
0
0~
responding rats in this combined treatment
group had CYP1A2 activities of 1410 ±171
nmol/mg/min.
Figure 2 shows the relationship
between hepatic porphyrin accumulation
and CYP1A2 activities, using MROD as a
marker, in TCDD, PCB 153, and co-
exposed rats. CYP1A2 activities and hepat-
ic porphyrin levels in the co-exposed ani-
mals were significantly correlated (p <0.05;
r= -0.792).
A tight band of CYP1A2 protein was
observed in all samples. However, in por-
phyrinogenic rats, a smear ofprotein stain-
ing throughout the gel was present in addi-
tion to the tight CYP1A2 band. Measure-
ments ofCYP1A2 protein levels in selected
samples in this experiment gave the same
optical density for TCDD-treated rats as
for rats co-exposed with PCB 153 (Table
3). No difference in CYP1A2 protein levels
was observed between the porphyrinogenic
rats (responders) and the nonporphyrino-
genic rats (nonresponders) after co-treat-
ment with the highest dose levels of
TCDD and PCB 153.
Using MROD as a marker and micro-
somes of a nonresponding and responding
(porphyrinogenic) rat in the highest dose
group in experiment 2 (TCDD/PCB 153),
increasing substrate concentrations of
methoxyresorufin up to 30 nM did not
restore MROD activities in vitro. In the in
vitro inhibition experiment with PCB 153
and PCB 126 using microsomes ofa nonre-
sponding and responding (porphyrinogenic)
rat, both PCB 153 and PCB 126 were able
to inhibit MROD activity. PCB 153 inhib-
ited MROD activity by 50% in both sam-
ples at a final concentration of 13 pg/ml. At
a final concentration of 13 ng/ml, reduc-
tions of50% and 25% were observed in the
responding and nonresponding rat. A final
concentration of 1.3 ng PCB 126/ml result-
ed in 25% and 15% reduction in MROD
activity in the responding and nonrespond-
ingrat, respectively.
Discussion
The work described in this study clearly
shows that porphyrins accumulate in the
liver after subchronic treatment with
TCDD, PCB 126, or PCB 156 in rats.
However, co-treatment of TCDD with
PCB 153 resulted in enhanced hepatic por-
phyrin levels, which was not observed in
the PCB 126/PCB 156 groups when co-
treated with TCDD. The reason for the
differences between the control groups in
10000
0C,
.>
a-
zip.
100
10
0.1
0 1000 2000 3000
CYP1A2(pmol/mg.min)
Figure 2. Correlation between microsomal CYPlA2
activities, measured as methoxyresorufin-0-
demethylase, and hepatic porphyrin accumulation
after 13 weeks on diets containing TCDD and PCB
153.
I Table 3. Rat hepatic CYPlA2 activity, measured as methoxyresorufin-O-demethylase, and protein levels
4 after 13weeks on diets containing PCB 153 and/orTCDD (means ± SE)
12
6
3
0
CYP1A2activity(ig/mg min)
Figure 1. Correlations between hepatic microso-
mal CYP1A2 activities, measured as 4-hydroxyla-
tion of acetanilide and hepatic porphyrins after 13
weeks on diets containing (A) TCDD, (B) PCB 126,
or(C) PCB 156. Correlation coefficients were 0.629
(p <0.001), 0.483 (p <0.01), and 0.808 (p<0.001) for
TCDD, PCB 126, and PCB 156, respectively.
Amount in diet CYPlA2 activity CYP1A2 protein
TCDD(pg/kg) PCB 153(mg/kg) (pmol/mg/min)a (optical density/pg protein)
0 0 185±5
0 lO 183 ± 18
o 30 156±23
0 100 123 ±19 0.013 ±0.004b
0.5 0 1195±45*
0.5 10 1258±59
0.5 30 628 ± 142**
0.5 100 441 ± 100**
5 0 1864± 50* 1.27 ± 0.16c
5 10 2021 ± 135
5 30 706 ± 392** 1.20 ±0.29c
5 100 888± 221** 1.32 ±0.26(responders)c
1.43 ± 0.10(nonresponders)b
an=4or5.
bn= 2.
cn= 3.
*Significantfrom control(leastsignificant difference test, p<0.05);**significantfrom corresponding TCDD
dose alone (leastsignificant difference test, p<0.05).
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the two experiments, or in general between
the two experiments (TCDD effect/lack of
effect) is not known. This difference was
not due to variability in the porphyrin
assay since all porphyrin samples were ana-
lyzed (both experiment 1 and 2) at the
same time using the same reagent solu-
tions, standards, and (positive) control
samples. In addition, the animals in the 5
pg TCDD/kg groups ate the same amount
of food in both experiments, so the doses
were comparable (Tables 1 and 2).
The porphyrinogenic activity of poly-
halogenated aromatic hydrocarbons is well
known (8-10,14,58). Jones and Sweeney
(14) postulated the involvement of an Ah
receptor-mediated mechanism in the accu-
mulation ofhepatic porphyrins by TCDD.
Using TCDD as a reference compound and
hepatic porphyrin accumulation as a mark-
er, the relative potencies derived from no-
observed-adverse-effect levels (NOAELs)
and lowest-observed-adverse-effect levels
(LOAELs) in the first experiment (Table 4)
were in the same range as those reported
using other well-known Ah receptor-medi-
ated effects using the same experimental
design (26,27,59). In mice, relative poten-
cies ofPCDDs, PCDFs, and PCBs derived
from hepatic porphyrin accumulation were
in the same range as those based on hepatic
CYPlAI and CYP1A2 induction (60). All
these results suggest the involvement of an
Ah receptor-mediated mechanism in hepat-
ic porphyrin accumulation. Moreover, this
is strengthened by the absence of hepatic
porphyrin accumulation after subchronic
dosingwith di-ortho-substituted PCBs, such
as PCB 153 (Table 1) (58) or 2,2',3',4,4',
5,5'-heptachlorobiphenyl (PCB 180) (61).
However, Stonard and Greig (58) also
found hepatic porphyrin accumulation by
subchronic administration of 2,2',3,
3',4,4'-hexachlorobiphenyl (PCB 128) and
2,2',3,4,4',5'-hexachlorobiphenyl (PCB
138) in rats.
It can be suggested that an Ah receptor-
mediated mechanism in hepatic porphyrin
accumulation involves the induction of
CYP1A2. Strong evidence for a CYP1A2-
related mechanism in the oxidation of uro-
porphyrinogen III to uroporphyrin III has
been reported by Lambrecht and co-work-
ers using hepatic rat microsomes and puri-
fied mouse CYP1A2 (62,63). In our study,
CYP1A2 activities were correlated with
hepatic porphyrin levels after administra-
tion of TCDD, PCB 126, or PCB 156
(Fig. 2). At the highest dose levels ofthese
compounds, CYP1A2 activities were maxi-
mally induced as reported earlier
(26,27,57). The lower correlation for PCB
126 might be a consequence of inhibition
ofthe catalytic activity ofCYP1A2 by PCB
126, which has been suggested to be a com-
petitive high-affinity binding inhibitor
(27,44,64,65). In addition, hepatic por-
phyrin levels were slightly but not signifi-
cantly decreased in rats treated with 20 pig
TCDD/kg diet compared to 5 pg
TCDD/kg diet. TCDD (5 pg/kg diet) co-
administered with 180 pg PCB 126/kg diet
resulted in slighdy lower hepatic porphyrin
levels compared to co-administration with
50 pg PCB 126/kg. The same trend was
observed in these specific groups for
CYP1A2 activities using 4-OH-AA as a
marker (26,27). Additionally, MROD
activitywas inhibited by PCB 126 and PCB
153 in vitro in the presented study.
However, PCB 126 was about 1000 times
more potent than PCB 153 for this effect in
vitro. The results of this study, combined
with the results from the literature, suggest
that the relative potencies ofthe single PCB
congeners for hepatic porphyrin accumula-
tion might be based on an Ah receptor
CYPIA2-mediated oxidation of uropor-
phyrinogen III to uroporphyrin III.
A strong synergistic porphyrin accumu-
lation occurred after co-administration of
PCB 153 and TCDD, leading to hepatic
porphyrin levels as high as 800-fold the
level of control animals (second experi-
ment). The accumulated hepatic por-
phyrins were uroporphyrin III and hep-
tacarboxylic porphyrin, which indicate
PCT-like effects (11,66). In contrast, co-
administration of PCB 126 or PCB 156
with TCDD yielded no further hepatic
porphyrin accumulation compared to the
highest single dose ofPCB or TCDD con-
geners (first experiment).
The synergism on porphyrin accumula-
tion in our study has been reported previ-
ously after co-administration of phenobar-
bital-type and 3-methylcholanthrene-type
inducing compounds. Co-administration
of 2,2',4,4',5,5'- and 3,3',4,4',5,5'-hexa-
bromobiphenyls or phenobarbital and
TCDD in cultured chick embryo hepato-
cytes resulted in synergistic porphyrin
accumulation (67,68). Additionally, induc-
tion of ALAS activity and inhibition of
UROD activity was synergistically affected
after co-administration ofTCDD and phe-
nobarbital in these chick hepatocytes (68).
In female Sprague-Dawley rats, a synergis-
tic response on hepatic porphyrin accumu-
lation was reported after 20-week co-expo-
sure of the 2,2',4,4',5,5'- and 3,3',4,
4',5,5'-hexabromobiphenyls (69).
It can be speculated that the cause for
the synergistic response after co-adminis-
tration with PCB 153 may be found in an
effect on the rate-limiting enzyme in heme
synthesis, ALAS. Phenobarbital has been
reported to induce both ALAS mRNA and
Table 4. No-observed-adverse-effect levels
(NOAELs) and lowest-observed-adverse-effect
levels (LOAELs) for porphyrin accumulation after
13-week exposure to TCDD, PCB 126, or PCB 156
and estimated relative potencies
Estimated
(pg/kg/day) relative potency
Compound NOAEL LOAEL NOAEL LOAEL
TCDD 0.026 0.047 1 1
PCB 126 0.47 3.18 0.06 0.014
PCB 156 81 365 0.0003 0.0001
enzyme activity in rat hepatocytes (70-73).
As PCB 153 and phenobarbital are well-
known CYP2B-inducing compounds, a
similar ALAS induction may have occurred
in our study. Both mechanisms, i.e., induc-
tion of ALAS by PCB 153 and enhanced
oxidation of uroporphyrinogen III to uro-
porphyrin III by CYP1A2, might have led
to the strong synergistic effect observed
after co-administration of the compounds.
This dual mechanism might explain the
high porphyrinogenic action of 2,2',3,
3',4,4'-hexachlorobiphenyl (PCB 128) and
2,2',3,4,4',5'-hexachlorobiphenyl (PCB
138), both di-ortho-substituted PCBs,
which also induced the Ah receptor-associ-
ated activity of benzo[a]pyrene hydroxyla-
tion (58). However, it should be noted that
the mixed-type inducer PCB 156 revealed
hardly any porphyrin accumulation in the
liver after 13 weeks ofexposure.
Co-administration of PCB 153 and
TCDD resulted in lower CYP1A2 activi-
ties, using MROD as a marker, compared
to TCDD alone (Table 3). In addition, an
inverse relationship was found between
hepatic porphyrin accumulation and
CYP1A2 activities in co-treated animals
(Fig. 2). However, TCDD-induced
CYP1A2 protein levels were unaffected by
co-treatment with PCB 153. All this infor-
mation suggests that under porphyrino-
genic conditions, CYP1A2 activity is
decreased while CYP1A2 protein levels
remain intact. This decreased activity could
not be restored by adding more substrate
(methoxyresorufin) during the assay, sug-
gesting that a tight-binding inhibitor has
been formed in vivo. Because free PCB 153
decreased CYP1A2 activities in vitro only
at the high concentration of 13 pg/ml, it is
unlikely that microsomal-bound PCB 153
from co-treated rats was responsible for the
inhibition ofCYP1A2 (Table 2).
Whether PCB 153 was left over in
these microsomes at all, since PCB 153 has
more affinity for fat tissue than for liver, is
an unanswered question. It has been
reported that under porphyrinogenic con-
ditions, a tight-binding inhibitor of
UROD is formed (74,75). Based on our
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results, it can be speculated that under the
same conditions, a tight-binding inhibitor
of CYP1A2 activity is also formed. This
suggestion is strengthened by the dose-
dependent inhibition in chicken hepato-
cyte CYPIA activity, using EROD as a
marker, after treatment with PCDDs and
PCBs (76-78). This dose-dependent inhi-
bition in CYPIA activity occurred at dose
levels that caused an increase in porphyrin
levels (76,78). Nevertheless, it remains
unclear why a large degree of variability
was observed in the PCB 153/TCDD co-
treatment group at the high dose levels of
both compounds. However, it can be
excluded that this was due to variability in
PCB 153 or TCDD concentrations in
hepatic tissue (46).
In summary, an Ah receptor-mediated
mechanism most likely plays a role in por-
phyrin accumulation after single-congener
exposure, as relative potencies of PCB 126
and PCB 156 are in the same range as
other well-known Ah receptor-mediated
effects. However, this porphyrin accumula-
tion is enhanced by the combined effect of
PCB 153 and TCDD, leading to an excep-
tionally high hepatic porphyrin accumula-
tion ofrats subchronically exposed to com-
binations of these compounds. We postu-
late that in this synergistic process a dioxin-
like induced CYP1A2 mechanism is
involved, leading to oxidation of uropor-
phyrinogen III to uroporphyrin III, togeth-
erwith induction ofALAS by PCB 153. In
addition, it can be speculated that high lev-
els ofTCDD ofPCB 126 decrease hepatic
porphyrin accumulation by tightly binding
to CYP1A2. We suggest that under por-
phyrinogenic conditions, a binding
inhibitor ofCYP1A2 is formed. The inter-
active effect on porphyrin accumulation
after co-administration of dioxinlike and
non-dioxinlike compounds may have sig-
nificant implications for the risk assessment
ofthese chemicals.
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